Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 5/2010

01-05-2010

Stage IV Rectal Cancer with Liver Metastases: Is There a Benefit to Resection of the Primary Tumor?

Authors: Christina Cellini, Steven R. Hunt, James W. Fleshman, Elisa H. Birnbaum, Andrew J. Bierhals, Matthew G. Mutch

Published in: World Journal of Surgery | Issue 5/2010

Login to get access

Abstract

Background

Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases. For patients with extensive liver metastases, FOLFOX and FOLFIRI have improved resection rates and survival. We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.

Methods

Patients with metastatic rectal cancer to liver were identified from a colorectal cancer database from 2002 to 2008. Patients received neoadjuvant chemoradiation and adjuvant FOLFOX or FOLFIRI therapy. The outcomes for patients who underwent synchronous resection, staged resection, resection of rectal tumor only, and no resection with chemotherapy only were compared. Statistical analysis was determined by ANOVA. Survival was determined using the Kaplan–Meier method.

Results

Seventy-four patients were identified: 30 synchronous resections, 13 staged resections, 22 primary resection only, and 9 no resection. Median follow-up was 23 months (range = 4-58 months). Sixty-five percent of patients underwent liver resection with 26% rendered eligible for resection after adjuvant therapy. Those who underwent primary resection only had shorter median survival than those who underwent either staged or synchronous liver resection (31 vs. 47 vs. 46 months, respectively; P = 0.17). Survival was no different for synchronous versus staged resection (P = 0.6). Volume of liver disease predicted resectability (P = 0.001). Without liver resection, 2-year survival was approximately 60%. Palliative surgery was required in six of nine patients who did not undergo resection of their primary tumor.

Conclusions

Current chemotherapeutic regimens lead to improved survival in patients with unresectable liver metastases. Upfront chemotherapy in the asymptomatic patient compared with resection of the primary tumor does not appear to significantly affect survival. However, given that 60% of patients were alive after 2 years, resection of the primary lesion for palliative reasons and local control must be considered.
Literature
1.
Yoon SS, Tanabe KK (1999) Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 4:197–208PubMed
2.
Martin R, Paty P, Fong Y et al (2003) Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 197:233–241 discussion 241-232CrossRefPubMed
3.
Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214CrossRefPubMed
4.
Arkenau HT, Arnold D, Cassidy J et al (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 26:5910–5917CrossRefPubMed
5.
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed
6.
Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed
7.
Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657 discussion 657-648CrossRefPubMed
8.
Rivoire M, De Cian F, Meeus P et al (2002) Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95:2283–2292CrossRefPubMed
9.
Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–520 discussion 520-502CrossRefPubMed
10.
Joffe J, Gordon PH (1981) Palliative resection for colorectal carcinoma. Dis Colon Rectum 24:355–360CrossRefPubMed
11.
Longo WE, Ballantyne GH, Bilchik AJ et al (1988) Advanced rectal cancer. What is the best palliation? Dis Colon Rectum 31:842–847CrossRefPubMed
12.
Ruo L, Gougoutas C, Paty PB et al (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196:722–728CrossRefPubMed
13.
Rosen SA, Buell JF, Yoshida A et al (2000) Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg 135:530–534 discussion 534-535CrossRefPubMed
14.
Scheer MG, Sloots CE, van der Wilt GJ et al (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19:1829–1835CrossRefPubMed
15.
Sarela AI, Guthrie JA, Seymour MT et al (2001) Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 88:1352–1356CrossRefPubMed
16.
Konyalian VR, Rosing DK, Haukoos JS et al (2007) The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis 9:430–437CrossRefPubMed
17.
Cook AD, Single R, McCahill LE (2005) Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 12:637–645CrossRefPubMed
18.
Mathis KL, Nelson H, Pemberton JH et al (2008) Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg 248:592–598PubMed
19.
Thelen A, Jonas S, Benckert C et al (2007) Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis 22:1269–1276CrossRefPubMed
20.
Nash GM, Saltz LB, Kemeny NE et al (2002) Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol 9:954–960CrossRefPubMed
21.
Al-Sanea N, Isbister WH (2004) Is palliative resection of the primary tumour, in the presence of advanced rectal cancer, a safe and useful technique for symptom control? ANZ J Surg 74:229–232CrossRefPubMed
22.
Law WL, Chu KW (2006) Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol 93:523–528CrossRefPubMed
23.
Eisenberger A, Whelan RL, Neugut AI (2008) Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis 23:559–568CrossRefPubMed
24.
Scoggins CR, Meszoely IM, Blanke CD et al (1999) Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 6:651–657CrossRefPubMed
25.
Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27(20):3379–3384CrossRefPubMed
26.
Scoggins CR, Campbell ML, Landry CS et al (2009) Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 16:35–41CrossRefPubMed
27.
Michel P, Roque I, Di Fiore F et al (2004) Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol 28:434–437PubMedCrossRef
Metadata
Title
Stage IV Rectal Cancer with Liver Metastases: Is There a Benefit to Resection of the Primary Tumor?
Authors
Christina Cellini
Steven R. Hunt
James W. Fleshman
Elisa H. Birnbaum
Andrew J. Bierhals
Matthew G. Mutch
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 5/2010
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-010-0483-7

Other articles of this Issue 5/2010

World Journal of Surgery 5/2010 Go to the issue

OriginalPaper

Nerve Growth Factor-β Expression Is Associated with Lymph Node Metastasis and Nerve Infiltration in Human Hilar Cholangiocarcinoma

OriginalPaper

Small Bowel Obstruction—Who Needs an Operation? A Multivariate Prediction Model

OriginalPaper

Outcome of Total Parathyroidectomy and Autotransplantation as Treatment of Secondary and Tertiary Hyperparathyroidism in Children and Adults

OriginalPaper

Predictor for Histological Microvascular Invasion of Hepatocellular Carcinoma: A Lesson from 229 Consecutive Cases of Curative Liver Resection

OriginalPaper

Surgical Training in Chile

OriginalPaper

Palliative Resection in Noncurative Gastric Cancer Patients